АКТУАЛЬНЫЕ ПРОБЛЕМЫ ЗДРАВООХРАНЕНИЯ
ORIGINAL ARTICLES
High prevalence and adverse prognosis of chronic heart failure (CHF) justify the need for further investigation of new complex treatment and rehabilitation approaches in these patients. The author assessed effectiveness of multi-disciplinary rehabilitation in patients with ischemic CHF. In total, the study included 255 patients with ischemic CHF I-IV (NYHA). Complex results of psychological correction, training walking courses (hospital and long-term (12 months) programs), with the use of Borg scale, were investigated. In patients with ischemic CHF, positive multi-disciplinary effects of psychological correction and physical training, in regard to psychological status and physical stress tolerability, were registered.

DIAGNOSTIC METHODS
GUIDELINES FOR THE PRACTITIONER
Clinical effectiveness of a new Russian antiarrhythmic agent nibentan, Class III, was studied in various supraventricular arrhythmias. In total, 220 patients with atrial fibrillation (AF), atrial flutter (AFl), supraventricular tachycardia (SVT) and frequent supraventricular extrasystoles (SVE) were examined. ECG monitoring and echocardiography data, electrolyte balance and blood biochemistry were assessed. left ventricular myocardial kinetics and perfusion were studied by computed Tc-99 scintigraphy (Siemens-E. CAM camera, two detectors, 90 degree rotation, 16 gates per cardiac cycle; data analysis with 4DM sped program). Nibentan pharmacokinetics and pharmacodynamics, as well as its metabolite levels, were measured with highly effective chromatography-mass spectrometry. Nibentan was highly effective in various supraventricular arrhythmias, without affecting central hemodynamics or left ventricular perfusion. There was a positive correlation between nibentan administration time, its active metabolite detection, plasma Mg level increase, and QTinterval elongation. Conclusion: Nibentan, a new antiarrhythmic agent, is highly effective for supraventricular paroxysmal arrhythmias (AF, AFl, SVT) management. Due to long QT and ventricular tachycardia risk, nibentan should be administered at cardiac resuscitation departments or intensive care units only.

EPYDEMIOLOGY AND PREVENTION
REVIEW
ANNIVERSARY
PRESS RELEASE
ISSN 2618-7620 (Online)